ARTICLES BY SUZANNE HODSDEN

  • Integra LifeSciences Acquirers Derma Sciences for $204M, Expands Regenerative Technology Offerings
    Integra LifeSciences Acquirers Derma Sciences for $204M, Expands Regenerative Technology Offerings

    Integra LifeSciences has entered into a definitive agreement to acquire Derma Sciences, a medtech specializing in tissue regeneration for advanced wound and burn care. 

  • Hill-Rom Expands Patient Monitoring Business With $330M Mortara Acquisition
    Hill-Rom Expands Patient Monitoring Business With $330M Mortara Acquisition

    Hill-Rom has signed a definitive agreement to acquire Mortara Instrument Inc. for an estimated $330 million. Integration of Mortara’s portfolio is expected to expand and enhance Hill-Rom’s offerings in the diagnostic cardiology and vital sign monitoring markets, as well as accelerate growth for Mortara technology on a global scale.

  • Senate Wavers On Repealing Device Tax, ACA Without Replacement
    Senate Wavers On Repealing Device Tax, ACA Without Replacement

    Support for a swift repeal of the Affordable Care Act (ACA) is wavering in the U.S. Senate, as many express concerns that a full repeal should be delayed until a replacement plan is fully-realized and a funding strategy is in place.

  • Orthofix Snags FDA Approval, CE Mark For ‘Smart’ Bone Growth Stimulation
    Orthofix Snags FDA Approval, CE Mark For ‘Smart’ Bone Growth Stimulation

    Orthofix announced both FDA and CE Mark approvals for its next-generation CervicalStim and SpinalStim bone growth stimulators (BGS), non-invasive devices that use low-level pulsed electromagnetic fields (PEMF) to enhance the healing process following orthopedic fusion surgeries.

  • New Technology Targets Vagus Nerve Stimulation To Treat Inflammatory Disease
    New Technology Targets Vagus Nerve Stimulation To Treat Inflammatory Disease

    New technology from the Georgia Institute of Technology targets vagus nerve stimulation (VNS) to improve its therapeutic benefit as a treatment for chronic inflammatory disease. 

  • FDA Issues Final Guidance For Medical Device Accessories
    FDA Issues Final Guidance For Medical Device Accessories

    While remaining consistent with the 2015 draft guidance in many respects, the finalized guidance clarifies the scope of the policy following the passage of the 21st Century Cures Act and describes in greater detail how manufacturers may obtain classification of a new accessory type via the de novo process.

  • First Real-Life Study Tests Feasibility Of Solar-Powered Implants
    First Real-Life Study Tests Feasibility Of Solar-Powered Implants

    Researchers in Switzerland have produced real-life evidence that implanted devices could one day be powered by solar energy. Study participants who wore solar power measurement devices throughout their regular daily activities generated the energy required to power the average contemporary pacemaker, regardless of the weather, season, or age.

  • Nikon, Verily Partnership Combines Machine-Learning With Advanced Retinal Imaging
    Nikon, Verily Partnership Combines Machine-Learning With Advanced Retinal Imaging

    Nikon and Verily have signed a strategic partnership to co-develop advanced screening technology for eye diseases associated with diabetes. By pairing machine-learning capabilities with next-generation retinal imaging, the companies hope to offer earlier diagnosis of diabetic retinopathy and diabetic macular edema — two leading causes of blindness worldwide.

  • Breathalyzer Diagnoses 17 Different Diseases Using A Single Breath
    Breathalyzer Diagnoses 17 Different Diseases Using A Single Breath

    A team of Israeli scientists has further developed its breathalyzer technology, and a recent clinical study demonstrated an 86 percent success rate identifying 17 different diseases. The researchers’ nanoarray uses data collected from over 1,400 subjects to establish “breathprints” for diseases like cancer and multiple sclerosis, and then relies upon artificial intelligence (AI) technology to make a diagnosis.

  • U.S. Regulators Set To Approve St. Jude Acquisition By Abbott
    U.S. Regulators Set To Approve St. Jude Acquisition By Abbott

    U.S. anti-trust regulators are set to approve the $25 billion acquisition of St. Jude Medical by Abbott Laboratories, according Reuters sources. The deal was approved by European regulators in November, contingent on the companies’ divestment of two cardiovascular devices to Terumo.

More Articles by Suzanne Hodsden

Suzanne Hodsden

Suzanne Hodsden is a contributor who writes regular life sciences news features for several publications. She holds degrees from Denison University and Bowling Green State University.